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Potential benefit of angiotensin II in COVID-
19 patients: beyond reasonable doubt?
António Tralhão1,2* , Luís Ferreira Moita3 and Pedro Póvoa1,4,5
We read with great interest the editorial by Busse et al.
on the potential use of angiotensin II in the treatment
of COVID-19 [1]. However, amidst the myriad of
attempted interventions, some may be more reasonable
than others [2].
In preclinical studies, SARS-CoV-1-mediated ACE-2
downregulation led to increased lung injury [3]. The
extrapolated protective role of ACE2 in human lung
infections seems to result from both the breakdown of
angiotensin II and the generation of Ang1–7 and Ang1–
9, anti-inflammatory, antioxidative, and antiproliferative
peptides that thwart the detrimental effects of angioten-
sin II in lung parenchyma [3]. Notably, angiotensin II re-
ceptor I blockade salvaged a rodent model from more
profound alveolar damage [3]. In a clinical setting, re-
combinant human ACE2 significantly reduced angio-
tensin II and hinted towards lower mortality in a small
randomized trial of undifferentiated ARDS patients [4].
Taken together, these studies cast little doubt on the
true colors of angiotensin II during severe COVID-19
pneumonia. Conversely, observational data have re-
vealed no harm and even disclosed potential benefit
associated with RAAS modulation [5]. Hence, the as-
sumption of Busse et al. is frankly counterintuitive.
Ongoing RCTs evaluating rhACE2 (NCT04335136),
AT-1 receptor blockade (NCT04312009), and ACEi/
ARB continuation or discontinuation after COVID-19
diagnosis (NCT04329195) are eagerly expected to shed
more light into present uncertainties.
Busse et al. advocate for the compassionate use of
angiotensin II in critically ill patients with supervening
shock and suggest it may even be used prophylactically.
In an aged population with cardiovascular comorbidities,
in which RAAS blockade has earned a pivotal protective
role for decades, such radical shift could have additional
unforeseen consequences. Angiotensin II effectively in-
creased blood pressure on top of norepinephrine in the
ATHOS-3 trial. Although certainly appealing and offer-
ing an alternative pathway to improve mean arterial
pressure and organ perfusion in vasodilatory shock,
more limb ischemia and de novo infections were also
noted, raising safety concerns. In severe COVID-19 pa-
tients, in whom the percentage of refractory shock in
unclear, the utility of a second vasopressor seems even
more unwarranted.
From our perspective, it appears unlikely and even
paradoxical to anticipate a net clinical benefit of angio-
tensin II in COVID-19. If reasonable doubt still persists,
this assumption should be put to the test like other
putative beneficial interventions [2]. Beyond their indi-
vidual plausibility, all proposed therapies in COVID-19
patients should be considered experimental and cannot
be universally recommended until evaluated in properly
conducted RCTs.
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Authors’ response
Angiotensin II for COVID-19-induced shock: beyond a reasonable doubt, an ACE in the hole
Michael T. McCurdy, Jonathan H. Chow, Ashish K.
Khanna, and Laurence W. Busse
We thank Tralhão et al. for bringing up important is-
sues regarding our commentary on the use of angioten-
sin II for vasodilatory shock in COVID-19 patients.
Given recent data to support continuing ACE-inhibition
in patients with COVID-19, we are not arguing to cease
such therapy in hemodynamically stable patients. How-
ever, those with vasodilatory shock are clearly not the
same as those on ACE-inhibitors, and the “pivotal pro-
tective role” of RAAS blockade has been associated with
increased risk of hemodynamic compromise in critically
ill patients [6]. We also caution against an argument
based on the pilot study by Khan et al. of recombinant
human ACE2 for patients with ARDS, which was halted
due to clinical futility and relies only on angiotensin II
levels, rather than the ratio of angiotensin II to angioten-
sin I, which may have greater clinical relevance [7, 8].
Dr. Tralhão’s argument that lung injury results directly
from increased angiotensin II levels due to virally medi-
ated downregulation of ACE-2 rather than from direct
viral invasion not only ignores basic human physiology
but also runs contrary to the currently available evi-
dence. Had increased levels of angiotensin II been detri-
mental to lung parenchyma, this would have been
suggested by the results of ATHOS-3, which showed no
such effect [9]. Further data support the safety of angio-
tensin II in patients with COVID-19. Zangrillo et al.
recently reported using angiotensin II for COVID-19-
induced vasodilatory shock in 16 patients, 10 of whom
received it as a first-line and only requisite vasopressor
[10]. Contrary to concerns expressed by Tralhão et al.,
patients treated with angiotensin II had significant
improvements in FiO2 (0.70 to 0.40), PEEP (14 to
11 cmH2O), and SpO2/FiO2 ratio (121.4 to 200.0) at 48
h. Despite staggeringly high global mortality rates for
COVID-19-induced vasodilatory shock, 14 of the 16
patients in this case series were alive at the time of the
authors’ submission of their report.
Cognizant of the dilemma of having to manage critically
ill patients in the absence of disease-specific data, we must
continue to rely on tangentially-related, randomized con-
trolled trials like ATHOS-3, as well as convincing clinical
experience, as provided by Zangrillo et al. We fully sup-
port Dr. Tralhão’s suggestion that well-designed studies
should inform our treatment options. While some clini-
cians may lack clinical equipoise regarding angiotensin II,
we still maintain that it should be evaluated in the setting
of COVID-19, based on a rational physiological argument
and emerging supportive data.
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